As people grow older, many develop more than one long-term health condition, such as high blood pressure, diabetes, arthritis, heart disease, or high cholesterol.
Because each condition often requires treatment, many older adults end up taking several medicines every day. Doctors call this polypharmacy, which usually means taking five or more regular medications.
While these medicines are often necessary, taking many drugs at once increases the chance of side effects, drug interactions, confusion about dosing, falls, and hospital visits.
Some doctors have wondered whether newer weight-loss medicines known as GLP-1 drugs could reduce this medication burden. These medicines help people lose weight and can improve conditions linked with obesity, including type 2 diabetes. If obesity contributes to several illnesses, treating obesity might allow patients to stop some of their other medicines.
Researchers at Yale University tested this idea in a new study published in the Journal of General Internal Medicine. They examined how much polypharmacy among adults aged 65 and older could actually be explained by obesity.
The results showed that obesity accounted for only about 15% of polypharmacy cases. In numbers, this represents roughly 3.3 million of the estimated 22 million older adults experiencing polypharmacy. Although this is a large number of people, it also means that about 85% of cases were caused by other health conditions rather than obesity.
These findings suggest that GLP-1 medicines may improve obesity and some obesity-related diseases, but they are unlikely to dramatically reduce the total number of medicines taken by most older adults.
Researchers also pointed out that GLP-1 medicines can themselves cause side effects such as nausea, vomiting, diarrhea, or acid reflux. Some patients may even need extra medicines to manage those problems.
The study comes at an important time because Medicare is expanding access to obesity medicines through a temporary demonstration program. Researchers expect many more older adults will begin using these drugs.
However, it is still unclear what will happen when the program ends, since higher costs could force some people to stop treatment. Previous research suggests stopping GLP-1 medicines may lead to weight regain and worsening insulin resistance.
This study provides an important reality check. GLP-1 medicines have many health benefits, but they are not a simple solution for reducing medication use in older adults. Most polypharmacy is caused by multiple chronic illnesses that cannot be solved by weight loss alone.
The study also reminds doctors to continue reviewing medication lists carefully and to stop unnecessary medicines whenever it is safe to do so.
Because this research estimated the contribution of obesity rather than testing patients directly in a clinical trial, future studies following older adults taking GLP-1 medicines over several years will provide stronger evidence.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about ginger’s journey in weight management ,and green tea: a cup of weight loss.
Source: Yale University.
